Non-Hodgkin Lymphoma Clinical Trials in Columbus, Ohio
19 recruitingColumbus, Ohio
Showing 1–19 of 19 trials
Recruiting
Phase 1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Phase 2
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 1
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+12 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT07166419
Recruiting
Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+12 more
AIDS Malignancy Consortium20 enrolled6 locationsNCT05077527
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company787 enrolled38 locationsNCT06876649
Recruiting
Phase 2
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma+5 more
Aseel Alsouqi24 enrolled3 locationsNCT05873712
Recruiting
Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company279 enrolled36 locationsNCT06876662
Recruiting
Phase 1
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type+6 more
Lapo Alinari18 enrolled1 locationNCT05755087
Recruiting
Phase 1
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+8 more
Nathan Denlinger18 enrolled1 locationNCT06209619
Recruiting
Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 1Phase 2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more
John Reneau12 enrolled1 locationNCT04848064
Recruiting
Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaSmall Lymphocytic Lymphoma+1 more
Imugene Limited135 enrolled23 locationsNCT03666000
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Non-Hodgkin LymphomaLymphomaLymphoma, Non-Hodgkin+4 more
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763